Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome

Abdelali Agouni, Anne Hélène Lagrue-Lak-Hal, Pierre Henri Ducluzeau, Hadj Ahmed Mostefai, Catherine Draunet-Busson, Georges Leftheriotis, Christophe Heymes, Maria Carmen Martinez, Ramaroson Andriantsitohaina

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

Microparticles are membrane vesicles that are released during cell activation and apoptosis. Elevated levels of microparticles occur in many cardiovascular diseases; therefore, we characterized circulating microparticles from both metabolic syndrome (MS) patients and healthy patients. We evaluated microparticle effects on endothelial function; however, links between circulating microparticles and endothelial dysfunction have not yet been demonstrated. Circulating microparticles and their cellular origins were examined by flow cytometry of blood samples from patients and healthy subjects. Microparticles were used either to treat human endothelial cells in vitro or to assess endothelium function in mice after intravenous injection. MS patients had increased circulating levels of microparticles compared with healthy patients, including microparticles from platelet, endothelial, erythrocyte, and procoagulant origins. In vitro treatment of endothelial cells with microparticles from MS patients reduced both nitric oxide (NO) and superoxide anion production, resulting in protein tyrosine nitration. These effects were associated with enhanced phosphorylation of endothelial NO synthase at the site of inhibition. The reduction of O2(-) was linked to both reduced expression of p47 phox of NADPH oxidase and overexpression of extracellular superoxide dismutase. The decrease in NO production was triggered by nonplatelet-derived microparticles. In vivo injection of MS microparticles into mice impaired endothelium-dependent relaxation and decreased endothelial NO synthase expression. These data provide evidence that circulating microparticles from MS patients influence endothelial dysfunction.
Original languageEnglish
Pages (from-to)1210-1219
Number of pages10
JournalAmerican Journal of Pathology
Volume173
Issue number4
Early online date4 Sep 2008
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Nitric Oxide Synthase Type III
Endothelium
Nitric Oxide
Endothelial Cells
NADPH Oxidase
Intravenous Injections
Superoxides
Superoxide Dismutase
Tyrosine
Healthy Volunteers
Flow Cytometry
Cardiovascular Diseases
Blood Platelets
Erythrocytes
Phosphorylation
Apoptosis
Injections
Membranes
Proteins
In Vitro Techniques

Keywords

  • Animals
  • Aorta
  • Blood Platelets
  • Cytokines
  • Endothelial Cells
  • Endothelium, Vascular
  • Female
  • Gene Expression Regulation
  • Health
  • Humans
  • Inflammation Mediators
  • Male
  • Metabolic Syndrome X
  • Mice
  • Middle Aged
  • Nitric Oxide
  • Nitric Oxide Synthase Type III
  • RNA, Messenger
  • Superoxides
  • Transport Vesicles
  • Vasodilation

Cite this

Agouni, A., Lagrue-Lak-Hal, A. H., Ducluzeau, P. H., Mostefai, H. A., Draunet-Busson, C., Leftheriotis, G., ... Andriantsitohaina, R. (2008). Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. American Journal of Pathology, 173(4), 1210-1219. https://doi.org/10.2353/ajpath.2008.080228

Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. / Agouni, Abdelali; Lagrue-Lak-Hal, Anne Hélène; Ducluzeau, Pierre Henri; Mostefai, Hadj Ahmed; Draunet-Busson, Catherine; Leftheriotis, Georges; Heymes, Christophe; Martinez, Maria Carmen; Andriantsitohaina, Ramaroson.

In: American Journal of Pathology, Vol. 173, No. 4, 10.2008, p. 1210-1219.

Research output: Contribution to journalArticle

Agouni, A, Lagrue-Lak-Hal, AH, Ducluzeau, PH, Mostefai, HA, Draunet-Busson, C, Leftheriotis, G, Heymes, C, Martinez, MC & Andriantsitohaina, R 2008, 'Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome', American Journal of Pathology, vol. 173, no. 4, pp. 1210-1219. https://doi.org/10.2353/ajpath.2008.080228
Agouni A, Lagrue-Lak-Hal AH, Ducluzeau PH, Mostefai HA, Draunet-Busson C, Leftheriotis G et al. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. American Journal of Pathology. 2008 Oct;173(4):1210-1219. https://doi.org/10.2353/ajpath.2008.080228
Agouni, Abdelali ; Lagrue-Lak-Hal, Anne Hélène ; Ducluzeau, Pierre Henri ; Mostefai, Hadj Ahmed ; Draunet-Busson, Catherine ; Leftheriotis, Georges ; Heymes, Christophe ; Martinez, Maria Carmen ; Andriantsitohaina, Ramaroson. / Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. In: American Journal of Pathology. 2008 ; Vol. 173, No. 4. pp. 1210-1219.
@article{c1dfaa04d5e441948da4da976c8dac18,
title = "Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome",
abstract = "Microparticles are membrane vesicles that are released during cell activation and apoptosis. Elevated levels of microparticles occur in many cardiovascular diseases; therefore, we characterized circulating microparticles from both metabolic syndrome (MS) patients and healthy patients. We evaluated microparticle effects on endothelial function; however, links between circulating microparticles and endothelial dysfunction have not yet been demonstrated. Circulating microparticles and their cellular origins were examined by flow cytometry of blood samples from patients and healthy subjects. Microparticles were used either to treat human endothelial cells in vitro or to assess endothelium function in mice after intravenous injection. MS patients had increased circulating levels of microparticles compared with healthy patients, including microparticles from platelet, endothelial, erythrocyte, and procoagulant origins. In vitro treatment of endothelial cells with microparticles from MS patients reduced both nitric oxide (NO) and superoxide anion production, resulting in protein tyrosine nitration. These effects were associated with enhanced phosphorylation of endothelial NO synthase at the site of inhibition. The reduction of O2(-) was linked to both reduced expression of p47 phox of NADPH oxidase and overexpression of extracellular superoxide dismutase. The decrease in NO production was triggered by nonplatelet-derived microparticles. In vivo injection of MS microparticles into mice impaired endothelium-dependent relaxation and decreased endothelial NO synthase expression. These data provide evidence that circulating microparticles from MS patients influence endothelial dysfunction.",
keywords = "Animals, Aorta, Blood Platelets, Cytokines, Endothelial Cells, Endothelium, Vascular, Female, Gene Expression Regulation, Health, Humans, Inflammation Mediators, Male, Metabolic Syndrome X, Mice, Middle Aged, Nitric Oxide, Nitric Oxide Synthase Type III, RNA, Messenger, Superoxides, Transport Vesicles, Vasodilation",
author = "Abdelali Agouni and Lagrue-Lak-Hal, {Anne H{\'e}l{\`e}ne} and Ducluzeau, {Pierre Henri} and Mostefai, {Hadj Ahmed} and Catherine Draunet-Busson and Georges Leftheriotis and Christophe Heymes and Martinez, {Maria Carmen} and Ramaroson Andriantsitohaina",
year = "2008",
month = "10",
doi = "10.2353/ajpath.2008.080228",
language = "English",
volume = "173",
pages = "1210--1219",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome

AU - Agouni, Abdelali

AU - Lagrue-Lak-Hal, Anne Hélène

AU - Ducluzeau, Pierre Henri

AU - Mostefai, Hadj Ahmed

AU - Draunet-Busson, Catherine

AU - Leftheriotis, Georges

AU - Heymes, Christophe

AU - Martinez, Maria Carmen

AU - Andriantsitohaina, Ramaroson

PY - 2008/10

Y1 - 2008/10

N2 - Microparticles are membrane vesicles that are released during cell activation and apoptosis. Elevated levels of microparticles occur in many cardiovascular diseases; therefore, we characterized circulating microparticles from both metabolic syndrome (MS) patients and healthy patients. We evaluated microparticle effects on endothelial function; however, links between circulating microparticles and endothelial dysfunction have not yet been demonstrated. Circulating microparticles and their cellular origins were examined by flow cytometry of blood samples from patients and healthy subjects. Microparticles were used either to treat human endothelial cells in vitro or to assess endothelium function in mice after intravenous injection. MS patients had increased circulating levels of microparticles compared with healthy patients, including microparticles from platelet, endothelial, erythrocyte, and procoagulant origins. In vitro treatment of endothelial cells with microparticles from MS patients reduced both nitric oxide (NO) and superoxide anion production, resulting in protein tyrosine nitration. These effects were associated with enhanced phosphorylation of endothelial NO synthase at the site of inhibition. The reduction of O2(-) was linked to both reduced expression of p47 phox of NADPH oxidase and overexpression of extracellular superoxide dismutase. The decrease in NO production was triggered by nonplatelet-derived microparticles. In vivo injection of MS microparticles into mice impaired endothelium-dependent relaxation and decreased endothelial NO synthase expression. These data provide evidence that circulating microparticles from MS patients influence endothelial dysfunction.

AB - Microparticles are membrane vesicles that are released during cell activation and apoptosis. Elevated levels of microparticles occur in many cardiovascular diseases; therefore, we characterized circulating microparticles from both metabolic syndrome (MS) patients and healthy patients. We evaluated microparticle effects on endothelial function; however, links between circulating microparticles and endothelial dysfunction have not yet been demonstrated. Circulating microparticles and their cellular origins were examined by flow cytometry of blood samples from patients and healthy subjects. Microparticles were used either to treat human endothelial cells in vitro or to assess endothelium function in mice after intravenous injection. MS patients had increased circulating levels of microparticles compared with healthy patients, including microparticles from platelet, endothelial, erythrocyte, and procoagulant origins. In vitro treatment of endothelial cells with microparticles from MS patients reduced both nitric oxide (NO) and superoxide anion production, resulting in protein tyrosine nitration. These effects were associated with enhanced phosphorylation of endothelial NO synthase at the site of inhibition. The reduction of O2(-) was linked to both reduced expression of p47 phox of NADPH oxidase and overexpression of extracellular superoxide dismutase. The decrease in NO production was triggered by nonplatelet-derived microparticles. In vivo injection of MS microparticles into mice impaired endothelium-dependent relaxation and decreased endothelial NO synthase expression. These data provide evidence that circulating microparticles from MS patients influence endothelial dysfunction.

KW - Animals

KW - Aorta

KW - Blood Platelets

KW - Cytokines

KW - Endothelial Cells

KW - Endothelium, Vascular

KW - Female

KW - Gene Expression Regulation

KW - Health

KW - Humans

KW - Inflammation Mediators

KW - Male

KW - Metabolic Syndrome X

KW - Mice

KW - Middle Aged

KW - Nitric Oxide

KW - Nitric Oxide Synthase Type III

KW - RNA, Messenger

KW - Superoxides

KW - Transport Vesicles

KW - Vasodilation

U2 - 10.2353/ajpath.2008.080228

DO - 10.2353/ajpath.2008.080228

M3 - Article

VL - 173

SP - 1210

EP - 1219

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 4

ER -